Theravance Biopharma Inc (TBPH)
9.17
-0.05
(-0.54%)
USD |
NASDAQ |
Apr 24, 16:00
9.165
0.00 (0.00%)
Pre-Market: 20:00
Theravance Biopharma Total Liabilities (Quarterly): 169.00M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 169.00M |
| September 30, 2023 | 167.46M |
| June 30, 2023 | 166.47M |
| March 31, 2023 | 167.99M |
| December 31, 2022 | 165.60M |
| September 30, 2022 | 282.92M |
| June 30, 2022 | 710.57M |
| March 31, 2022 | 706.81M |
| December 31, 2021 | 713.39M |
| September 30, 2021 | 726.70M |
| June 30, 2021 | 729.62M |
| March 31, 2021 | 748.33M |
| December 31, 2020 | 772.81M |
| September 30, 2020 | 773.72M |
| June 30, 2020 | 766.67M |
| March 31, 2020 | 763.34M |
| December 31, 2019 | 632.67M |
| September 30, 2019 | 628.14M |
| June 30, 2019 | 629.67M |
| March 31, 2019 | 644.52M |
| December 31, 2018 | 611.82M |
| Date | Value |
|---|---|
| September 30, 2018 | 384.41M |
| June 30, 2018 | 386.98M |
| March 31, 2018 | 416.70M |
| December 31, 2017 | 326.22M |
| September 30, 2017 | 302.04M |
| June 30, 2017 | 302.76M |
| March 31, 2017 | 294.09M |
| December 31, 2016 | 289.02M |
| September 30, 2016 | 58.42M |
| June 30, 2016 | 52.90M |
| March 31, 2016 | 54.59M |
| December 31, 2015 | 57.05M |
| September 30, 2015 | 34.96M |
| June 30, 2015 | 31.80M |
| March 31, 2015 | 35.79M |
| December 31, 2014 | 47.98M |
| September 30, 2014 | 41.88M |
| June 30, 2014 | 45.83M |
| March 31, 2014 | 44.08M |
| December 31, 2013 | 42.21M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
165.60M
Minimum
Dec 2022
773.72M
Maximum
Sep 2020
548.52M
Average
706.81M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 114.81M |
| Nektar Therapeutics | 267.05M |
| Vanda Pharmaceuticals Inc | 103.53M |
| Fate Therapeutics Inc | 137.80M |
| FibroGen Inc | 585.73M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 382.00M |
| Shareholders Equity (Quarterly) | 213.00M |
| Current Ratio | 5.392 |